STAAR Surgical Q2 sales exceed $90 million led by Asia growth
STAAR Surgical reported preliminary Q2 net sales exceeding $90 million, more than doubling the $44.3 million from the prior year, driven by sequential growth in China and solid momentum in the Americas. While EMEA faced a low single-digit decline due to Middle East tensions, the region excluding the Middle East achieved double-digit growth. The company noted that distributor inventory in China has normalized, and it remains focused on resolving ERP system challenges in the third quarter.
*this image is generated using AI for illustrative purposes only.
STAAR Surgical Company expects preliminary net sales for the second quarter ended July 3, 2026, to exceed $90 million, more than doubling the $44.3 million recorded in the same period of 2025. The surge in sales was led by sequential growth in China, solid growth across the broader Asia-Pacific region, and double-digit percentage growth in the Americas. The company disclosed these figures ahead of its full quarterly earnings announcement scheduled for August 12, 2026.
Regional Performance
While the EMEA region saw net sales decline by a low single-digit percentage due to ongoing turmoil in the Middle East, the area excluding the Middle East achieved double-digit percentage growth. Net sales in the Middle East, as well as certain parts of the EMEA and Asia-Pacific regions, continued to be adversely affected by significant geopolitical and macroeconomic headwinds. As of the end of the second quarter of 2026, distributor inventory in China appears to be within the Company’s targeted range to appropriately service the refractive market, contrasting with the prior year when shipments were minimal while distributors worked through excess inventory.
Financial Overview
The anticipated revenue marks a substantial year-over-year increase for STAAR Surgical. The following table outlines the preliminary sales figures for the reported periods.
| Period | Net Sales |
|---|---|
| Q2 2026 (Preliminary) | > $90 million |
| Q2 2025 | $44.3 million |
Operational Outlook
Warren Foust, Co-CEO, President and Chief Operating Officer, attributed the results to the strength of the team’s execution and the diversity of global commercial operations. He noted that while geopolitical and macroeconomic pressures persist and the ERP system implementation presented operational challenges, the company remains focused on resolving system issues in the third quarter. The Company’s three core strategic objectives for 2026 are revenue growth, profit expansion, and innovation acceleration.
The financial information in this release is unaudited and subject to adjustment. STAAR Surgical is scheduled to issue its complete quarterly earnings report on August 12, 2026.
How will the resolution of ERP system implementation challenges in the third quarter impact operational efficiency and profit margins?
What strategies will STAAR Surgical employ to mitigate the ongoing geopolitical and macroeconomic headwinds affecting the Middle East and parts of EMEA?
Will the double-digit sales growth in the Americas and Asia-Pacific be sustainable through the second half of 2026?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
